glp-1 and osteoporosis Treatment of Diabetes Osteoporosis—A Reciprocal Risk? GLP-1 weight loss drug study

(G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis

Blood 134 , 3253 (2019)

Oculomotor palsy in diabetics

Medical experts warn theres no scientific evidence supporting microdosing, and the term microdose lacks a clear definition in the medical community

The common thread across the research: the testosterone benefit appears to be driven primarily by weight loss , rather than by GLP-1s acting directly on the hormone system

Monitoring and prohibition status are reviewed annually, so any athlete should check the current year's Prohibited List and confirm with their national anti-doping organisation rather than relying on a summary